Latest news with #Chalke
The Province
28-05-2025
- Politics
- The Province
B.C. Ombudsperson Jay Chalke announces 2026 retirement after 10 years on the job
Chalke oversaw the implementation of new responsibilities under B.C.'s Public Interest Disclosure Act, which provides secure channels for public employees to report serious workplace wrongdoing Published May 27, 2025 • Last updated 7 hours ago • 1 minute read Ombudsperson Jay Chalke in 2017 Photo by DARREN STONE / TIMES COLONIST / PNG B.C.'s longest-serving ombudsperson has announced he will retire from his role in early 2026. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Jay Chalke has been in the role for a decade and oversaw the implementation of new responsibilities under B.C.'s Public Interest Disclosure Act, which provides secure channels for public employees to report serious workplace wrongdoing. He says in a news release that he didn't make the decision lightly, and serving as B.C.'s ombudsperson has been 'the honour' of his career. He says he is 'deeply proud' of the work he has accomplished, but he believes it's time for 'new perspectives and fresh leadership to continue (the) important work in ensuring fairness in public administration.' In the release, Chalke's office called him a steadfast advocate for fairness and accountability. It says the process to appoint a new ombudsperson will be led by the legislature and will begin soon to ensure a smooth transition. 'I am grateful to the dedicated team at the Office of the Ombudsperson and to the people of British Columbia for the trust they have placed in me,' Chalke says in the release. 'I look forward to supporting the transition and watching this office continue to make a difference.' News Vancouver Canucks Vancouver Canucks Hockey News
Vancouver Sun
27-05-2025
- Business
- Vancouver Sun
B.C. Ombudsperson Jay Chalke announces 2026 retirement after 10 years on the job
VICTORIA — B.C.'s longest-serving ombudsperson has announced he will retire from his role in early 2026. Jay Chalke has been in the role for a decade and oversaw the implementation of new responsibilities under B.C.'s Public Interest Disclosure Act, which provides secure channels for public employees to report serious workplace wrongdoing. He says in a news release that he didn't make the decision lightly, and serving as B.C.'s Ombudsperson has been 'the honour' of his career. He says he is 'deeply proud' of the work he has accomplished, but he believes it's time for 'new perspectives and fresh leadership to continue (the) important work in ensuring fairness in public administration.' Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. In the release, Chalke's office called him a steadfast advocate for fairness and accountability. It says the process to appoint a new ombudsperson will be led by the legislature and will begin soon to ensure a smooth transition. 'I am grateful to the dedicated team at the Office of the Ombudsperson and to the people of British Columbia for the trust they have placed in me,' Chalke says in the release. 'I look forward to supporting the transition and watching this office continue to make a difference.'
Winnipeg Free Press
27-05-2025
- Politics
- Winnipeg Free Press
B.C. Ombudsperson Jay Chalke announces 2026 retirement after 10 years on the job
VICTORIA – British Columbia's longest-serving ombudsperson has announced he will retire from his role in early 2026. Jay Chalke has been in the role for a decade and oversaw the implementation of new responsibilities under B.C.'s Public Interest Disclosure Act, which provides secure channels for public employees to report serious workplace wrongdoing. He says in a news release that he didn't make the decision lightly, and serving as B.C.'s Ombudsperson has been 'the honour' of his career. He says he is 'deeply proud' of the work he has accomplished, but he believes it's time for 'new perspectives and fresh leadership to continue (the) important work in ensuring fairness in public administration.' In the release, Chalke's office called him a steadfast advocate for fairness and accountability. It says the process to appoint a new ombudsperson will be led by the legislature and will begin soon to ensure a smooth transition. 'I am grateful to the dedicated team at the Office of the Ombudsperson and to the people of British Columbia for the trust they have placed in me,' Chalke says in the release. 'I look forward to supporting the transition and watching this office continue to make a difference.' This report by The Canadian Press was first published May 27, 2025.
Winnipeg Free Press
06-05-2025
- Business
- Winnipeg Free Press
B.C. ombudsperson finds request for repayment of provincial COVID-19 aid unjust
VICTORIA – British Columbia's ombudsperson says the provincial government unfairly required some workers to repay $1,000 they received after losing their jobs during the COVID-19 pandemic. The BC Emergency Benefit for Workers was introduced in 2020 and, in an effort to work quickly, the B.C. government initially required recipients to also be receiving the federal Canada Emergency Response Benefit. Jay Chalke's office says in a news release that the province was unaware that some people who had lost their job due to COVID-19 were being paid through other federal benefits, including employment insurance. Ombudsperson Jay Chalke releases a report during a press conference in Victoria, April 6, 2017. THE CANADIAN PRESS/Chad Hipolito He says the B.C. government paid those applicants, then ordered them to repay the funds. Chalke says people applied for the benefits in good faith to get through a crisis, then were ordered to pay back the money, not because they lost their jobs, but because of how a federal benefit claim was processed behind the scenes. His report makes one recommendation that the Finance Ministry change the Income Tax Act to extend the benefit eligibility to workers who lost their jobs due to COVID-19 but were excluded only because of employment insurance claims. Chalke says 'it was unjust for the province to require repayment in such circumstances.' Winnipeg Free Press | Newsletter Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. Sign up for The Warm-Up The report also found some eligible workers were told to repay even though they met all the criteria. It says the repayment letters people received were confusing and offered no explanation as to why they were being asked to repay the benefit. The report also says the ministry did not use available federal data to verify their eligibility and instead placed the burden on the individual. 'This report isn't about trying to undo a program that was created in a hurry,' Chalke says. 'It's about what governments do when they later find out that parts of those programs were flawed.' This report by The Canadian Press was first published May 6, 2025.
Mint
28-04-2025
- Business
- Mint
US generics, domestic market to drive healthy sales growth for pharma companies in Q4
Pharma companies are expected to report healthy revenue growth of 11-13% in the fourth quarter of FY25, driven by strong traction in niche US generic drugs, steady domestic performance in a seasonally weak quarter, and higher sales of a blockbuster cancer drug in the US before its distribution exclusivity ends next year, analysts said. Uncertainties over US tariffs and the end of the limited competition period for generic Revlimid in the US loom in the months ahead. However, analysts anticipate higher sales of Revlimid to drive growth for US-focused companies such as Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd and Sun Pharmaceutical Industries Ltd in Q4 and the first few quarters of the next fiscal. 'We expect a fine 4QFY25 for our pharma coverage, led by continued stability in US generics pricing, along with traction across most other markets, with sluggish domestic growth in January and February being the key chagrin," analysts at Kotak Institutional Equities said in a note. They expect year-on-year sales growth at about 11% and Ebitda growth at about 17%. JM Financial has similar estimates. 'They will deliver 10-11% top-line growth… generally, the fourth quarter is a softer quarter for some of the pharma companies with India exposure, especially in the acute [segment]," Amey Chalke, pharma research analyst at JM Financial, told Mint . 'Companies with strong US exposure typically tend to do well during the fourth quarter." Companies including Dr. Reddy's, Cipla, Sun Pharma, Zydus Lifesciences, Natco Pharma and Aurobindo Pharma have cashed in on generic versions of the $8 billion blood cancer drug Revlimid, distributed in restricted quantities in the US since March 2022. The companies are set to lose exclusivity on distribution of the drug in January 2026. Analysts anticipate Revlimid will push growth for Q4 of FY25 and the next few quarters. 'A lot of these companies which are reporting good numbers in the US, particularly, are benefiting from Revlimid. So, although Revlimid was also there in last year's quarter, this year's quarter we expect higher sales than last year," Chalke said. However, price erosion and quarterly volatility are expected. 'We expect a rise in quarterly volatility for gRevlimid revenues… We expect some price erosion, as most companies intend to sell allotted volumes for the year before September 2025," Nomura analysts said in a note. Revlimid sales might rise sequentially for Zydus and Sun Pharma but might decline for Dr Reddy's, the analysts noted. Nomura analysts peg sales growth at 13% for Q4. Analysts will also watch for product launches that companies have lined up in FY26 to make up for the loss of revenue from the loss of Revlimid exclusivity. It is estimated that most companies will see some correction in their profitability after the exclusivity period. Apart from Revlimid, overall US generic drugs have driven growth for companies. 'We note exports to the US increased significantly q-q for Zydus, Sun Pharma, Lupin, and Cipla in 4QFY25F, and reduced for Dr Reddy's," the Nomura analysts said. 'Excluding gRevlimid, we believe q-q US sales rose for Zydus (Sitagliptin) and Lupin (Mirabegron, PredForte, gXarelto) on other product specific opportunities in 4QFY25F." While pharmaceuticals are currently exempted from reciprocal tariffs by the US, President Donald Trump has indicated several times that a 'major" tariff on pharma imports will be imposed, sparking concerns for Indian exporters. This quarter, any comments on steps being taken by companies to mitigate the hit from potential tariffs would be key to monitor, analysts at Kotak Institutional Equities said. Domestic growth in the fourth quarter is typically weak, especially for drugmakers that are stronger in the acute therapy segment to treat short-term, severe conditions such as respiratory ailments, cough and cold. Growth of respiratory and anti-infective drugs are expected to have slowed, while cardiac and gastro drugs have likely outperformed, the Nomura analysts said. While organic domestic growth may be slower, overall domestic growth for companies is expected to benefit from acquisitions and in-licensing deals. Analysts at Kotak anticipate domestic sales growth for its coverage companies in the range of 7% to 18% year-on-year. 'Within our coverage, 4QFY25 domestic sales for companies such as Cipla, Dr Reddy's, Emcure and JB Chemicals would benefit from in-licensing deals, executed over the past few quarters, despite a sluggish offtake in January and February," the analysts noted, adding that Mankind and Emcure would demonstrate the highest growth within its coverage companies.
